The role of interleukin-6 (IL-6) in the growth of B cell derived hairy cell leukemia (HCL) was characterized.
. HCs can be stimulated to proliferate in vitro with B cell growth factor (BCGF), which has been proposed as an autocrine growth factor in this disease (3, 5) . Tumor necrosis factor (TNF) has also been reported to be an autocrine growth factor in HCL, since in vitro culture with TNF induces HCs to proliferate and to generate both TNF mRNA and protein (6) . Finally, the combination of interleukin-4 (IL-4) and IL-5 also induces in vitro DNA synthesis by HCs, although neither factor alone affects HC growth (7, 8) . Although these lymphokines have demonstrated in vitro effects, their role in the pathophysiology of HCL is not yet delineated.
Interleukin-6 triggers the terminal differentitation of normal B cells and has been shown to induce the growth ofmurine plasmacytomas and hybridomas and Epstein Barr Virus-transformed human B lymphocytes (9) (10) (11) (12) . It has also been proposed to be either an autocrine or paracrine growth factor in human chronic lymphocytic and acute myelocytic leukemia, non-Hodgkin's lymphoma and multiple myeloma cells (13) (14) (15) (16) (17) (18) (19) (20) . In vitro evidence exists for both autocrine and paracrine mechanisms of IL-6 stimulation of myeloma cell line growth (21) (22) (23) (24) . Moreover, high serum IL-6 levels observed in patients with advanced myeloma and plasma cell leukemia, coupled with transient inhibition of myeloma cell growth using anti-IL-6 antibodies in vivo, suggest a role for IL-6 in the pathophysiology of myeloma (25, 26) . Previous studies in HCL suggest that tumor cells do not respond to IL-6 in vitro (7, 8) .
Although both IL-6 mRNA and IL-6 protein have both been reported in HCs (7, 27) , its role in regulation ofHCL growth is not precisely defined.
In the present report, the role of IL-6 in the regulation of HCL growth was characterized. Purified tumor cells expressed functional cell surface IL-6 receptors (IL-6Rs), were IL-6 mRNA positive by PCR, and secreted low levels of IL-6 in vitro; however, neither exogenous IL-6 nor neutralizing antibody to (28) . The populations of enriched leukemia cells were also examined using mAbs directed at B, T, and myeloid antigens (Ags) in indirect immunofluorescence assays as previously described (7) . Monoclonal reagents used to characterize the HCs included the following: anti-B4(CD 19), Bl (CD20), B2(CD2I), interleukin-2R(IL-2R; CD25), and PCA-1, which are reactive with B cells at various stages ofdifferentiation; anti-T3(CD3), T4(CD4), and T8(CD8), which identify T cells; antiMol (CDl lb) and Mo2(CD14), which stain monocytoid cells; and anti-IL-6 receptor (MT-18), kindly provided by T. Taga (29) (30) (31) (32) (33) (34) (35) (36) (37) .
Culture ofHCs with growthfactors, IL-6 antisense, sense, and missense oligonucleotides, anti-IL-6 antibody and 2-chlorodeoxyadenosine. Recombinant IL-6 was generously provided by Dr. Steven Clark (Genetics Institute, Cambridge, MA). TNF was a gift from Dr. Donald Kufe (Dana-Farber Cancer Institute, Boston, MA). These factors were used at concentrations of maximal activity in standard assays based upon previous work (7) . A 15 base antisense oligonucleotide, specific for a sequence in exon II of the IL-6 gene previously described as effective in reducing growth in Kaposi sarcoma cells (38) , a control sense oligonucleotide and a control missense oligonucleotide of the same base compostion were synthesized by cyanoethyl phosphoramidite methodology. The oligonucleotides were purified by Sephadex column and ethanol precipitation and resuspended in sterile water. The oligonucleotides were used at a concentration of 15 ,M. A murine neutralizing mAb against IL-6 was provided by Dr. Edward Alderman (Genetics Institute) and used at a concentration ( 1:100), which blocks 100 U/ml of IL-6 in standard assays. The compound 2-chlorodeoxyadenosine (2-cda) was provided by Dr. David Gordon (R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ) and used at concentrations reported previously to have in vitro cytotoxicity for HCL (39 MN) . HCs were washed and incubated with IL-6PE according to manufacturer's directions. Labeled cells were enumerated by flow cytometric analysis using an Epics C cell sorter (Coulter Electronics, Hialeah, FL). Cell samples were incubated with excess unlabeled IL-6 ( 1,000 U/ml) to demonstrate specificity of IL-6PE binding. The U266 myeloma cell line, known to strongly express IL-6R (24) , and the CEM T acute lymphoblastic leukemia cell line served as positive and negative controls, respectively.
Northern blot analysis. Total cellcular RNA was isolated from HCs by the method ofChomczynski and Sacchi (40) . Polyadenylated RNA was isolated by the use ofoligo (dT) cellulose methodology (Invitrogen Corp., San Diego, CA). RNA samples were fractionated on 1.0% agarose gel with 6% formaldehyde and transferred onto a nylon membrane filter (Magnagraph; Micron Separations Inc. [MSIJ, Westboro, MA). The blots were prehybridized according to manufacturer's recommendations.
Hybridization was performed using probes for IL-6 and IL-6R. A full-length IL-6 cDNA was provided by Dr. S. Clark (Genetics Institute). A Ban II-Taq I fragment (nucleotides 215-657) was labeled by random oligonucleotide priming using alpha32P-labeled deoxyribonucleotide and Klenow fragment of DNA polymerase I. Hybridization took place at 420C in the presence of 2X SSC, 50% formamide, 5x Denhardt's, and 100 mg/ml denatured salmon sperm DNA. Filters were rinsed in decreasing concentrations of SSC and SDS at 50'C to a final stringency of 0.1 x SSC for 15 min and exposed to X-AR5 x-ray film (Kodak, Rochester, NY) at -70'C using intensifying screens. T24, a human urothelial tumor cell line known to secrete IL-6, served as a positive control for IL-6 mRNA. Polyadenylated RNA from the HCs was probed for IL-6R mRNA using a Pst-Xho I fragment (nucleotides 578-1764) of IL-6R cDNA (gift from T. Taga) (41) . Filters were rehybridized with human glyceraldehyde 3-phosphate dehydrogenase to confirm equivalent loading of RNA. PCR analysis. cDNA was synthesized from 1 gg samples of total RNA from the T24 cell line and from HCs using M-MLV reverse transcriptase (200 U/,ul) (BRL, Gaithersburg, MD). The reverse transcriptase reaction product was used for subsequent PCR amplification of specific cDNA through the use of oligodeoxynucleotide primers spanning 639 base pairs of IL-6 mRNA (24 bp; nucleotide sequences 34 through 672). The specific PCR reaction parameters were as follows: 30 cycles of 1 min at 94°C, 1 min at 60°C,3 min at 72°C followed by a 7-min extension at 72°C. The PCR reaction mixture contained 32P-labeled dCTP (4 MCi/ml) The PCR product was electrophoresed in 5.0% acrylamide gel, and the PCR fragments were analyzed by autoradiography using exposure to X-AR5 x-ray film.
Measurement of IL-6 bioactivity. IL-6 levels in the supernatants obtained from 3-d or 7-d cultures of HCs were measured in a bioassay by using IL-6 dependent B9 cells as previously described (42) . Test samples were heat-inactivated and sterile filtered before use. Varying dilutions of the test samples or IL-6 were added to wells containing 5 X I0 3 B9 cells for 72 h, with the addition of3[ H ]TdR for the last 4 h of culture. Thymidine uptake by the B9 cells was determined as described above.
Western blot analysis. The presence of the IL-6 protein in in HCs was assayed through the use of immunoblotting utilizing a murine anti-IL-6 mAb. Equal aliquots of cells were lysed in 1% NP-40 and the detergent solubilized protein was electrophoresed through a 17.5% SDS polyacrylamide gel (PAGE). Protein was transferred to nitrocellulose (Nitroplus 2000; MSI) in a Hoefer mini-Transphor unit for 14 h at 75 mA. The nitrocellulose filters were then preincubated in PBS containing 2% BSA. The filters were incubated with anti-IL-6 mAb at a concentration of 1: 1,000 for 1 h, washed extensively, and then incubated with a second antibody (peroxidase-conjugated goat anti-mouse IgG). The blots were further washed and developed with 3,3"-diaminobenzidine tetrahydrochloride.
Results
Morphologic, histochemical, and phenotypic characterization of HCL populations. Ficoll-Hypaque mononuclear cells were obtained from the spleens of four patients with HCL. T cells and monocytes were depleted by E-rosetting followed by adherence to plastic. The E-rosette negative nonadherent cell population demonstrated the morphological features of HCs by Wright-Giemsa staining and was TRAP positive. The cell surface phenotype is displayed in Fig. 1 A) ; in contrast, no binding ofIL-6 PE was observed on the T acute lymphoblastic leukemia cell line CEM, which is nonresponsive to IL-6 (Fig. 1 B) . 80-85% strong binding of IL-6 PE to HCs from four patients was noted ( Fig. 1 C and D) . This was specific, as evidenced by complete blocking of IL-6 PE binding to HCs preincubated with an excess of unlabeled IL-6. No significant changes in IL-6 binding were noted in HCs cultured with TNF for 3 d (Fig. 1 E) .
Expression ofIL-6 and IL-6 receptor mRNA transcripts in HCs. The expression of IL-6 mRNA in total RNA isolated from HCs was examined by Northern blot analysis. The 1.3 kb transcript for IL-6 mRNA was present in the T24 bladder cell line (Fig. 2 A, lane 1) but was absent in the CEM cell line (lane 2) and freshly isolated HCs (lanes 3 and 4) . In contrast, mRNA was demonstrated after 3 d ofculture with TNF ( Fig. 3 A, lanes 5 and 6). With increased sensitivity using PCR amplification, IL-6 mRNA was again observed in T24 (Fig. 2 B , lane 1) and lacking in CEM cells (lane 2). It was readily detectable in freshly isolated HCs both before (lanes 3 and 4) and after 3 d of culture with TNF (lanes 5 and 6).
Expression ofIL-6R mRNA, as evidenced by a single 5.3 kb band on Northern blot analysis of polyadenylated RNA, was present in the RPMI 8226 myeloma cell line (Fig. 3, lane 1 Fig. 4 , low levels (5±0.9 U/ml) ofIL-6 were secreted by HCs cultured in media alone. Culture with TNF reproducibly increased IL-6 secretion by HCs threefold (16.1±2.4 U/ml). B9 cells were not stimulated when cultured with TNF alone. Culture with IL-6 antisense oligonucleotide inhibited (> 90%) TNF-induced IL-6 secretion by HCs (1.4±0.4 U/ml IL-6). In contrast, IL-6 secretion in the presence of TNF and IL-6 sense oligonucleotide (12.7±4.5 U/ml) was not significantly different from that triggered by TNF. IL-6 missense oligonucleotide also did not alter IL-6 secretion induced by TNF (data not shown).
Expression ofintracytoplasmic IL-6 protein. cleotide specifically inhibited both DNA synthesis and IL-6 secretion triggered by TNF. These data suggest that IL-6 mediates the effects ofTNF on HCL growth via an intracytoplasmic mechanism.
Previous studies have suggested that HCL is of B cell origin and may represent a pre-plasma cell malignancy ( 1) . Since IL-6 triggers terminal differentiation of normal B cells and has been proposed as either an autocrine or paracrine growth factor for myeloma (16) (17) (18) (19) (20) , it was of interest to characterize its role in HCL growth. In this and other (7, 8) BCGF have previously been reported to be autostimulatory growth factors in HCL (3, 5, 6) ; moreover, increased serum levels of TNF have been noted in patients with HCL, suggesting that it may play a role in HCL growth in vivo (43, 44) . Our results confirm that TNF augments DNA synthesis by purified HCs in vitro. In addition, the blocking ofthis response by IL-6 antisense oligonucleotide, but not by anti-IL-6 neutralizing mAb, suggests that it is mediated by IL-6 in an intracytoplasmic mechanism. This is analogous to previous reports of autocrine systems wherein cell growth is insensitive to exogenous growth factors and neutralizing antibodies are unable to inhibit proliferation (45) (46) (47) (48) (49) . Such systems are compatible with a mechanism whereby receptor association and signal transduction both occur internally. This intriguing paradox in regulation in which a growth factor lacks activity when binding to an external receptor but appears functional in an internal mechanism (i.e., when binding to the identical receptor within the cytoplasm) warrants further study. The interplay of IL-6 and TNF has also been noted in other systems. Brach et al., for example, reported that TNF enhanced IL-6 mRNA transcripts in monocytes (50). These authors further demonstrated that both TNF and lymphotoxin bound to the same receptor, but the former enhanced steady state levels of IL-6 mRNA transcripts in monocytes due to mRNA stabilization, whereas the latter shortened IL-6 mRNA half-life. This observation may have relevance in HCL since TNF-a, but not lymphotoxin, stimulates cell growth (51 ) . In B cells, activation triggers TNF earlier than IL-6, but both are required for Ig secretion (52) . Moreover, anti-TNF antibody partially blocks IL-6 production and Ig secretion by normal B cells. Finally, increased levels of IL-6 mRNA transcripts have been demonstrated in acute myeloblastic leukemia blasts and polymorphonuclear neutrophils, respectively, after stimulation with TNF (53, 54) . Thus, TNF induces IL-6 production in a variety of normal and malignant cells.
Interferon-a and 2-cda have demonstrated efficacy in the treatment of HCL (55), but their exact mechanism ofaction is unknown. Interferon-a has been shown to inhibit in vitro DNA synthesis induced in HCs by various growth factors (4, 7, 8, 56) . It induces ultrastructural alterations in HCs, supporting the notion that it impairs HC responsiveness to B cell growth factors by altering the target cells (56) . In B chronic lymphocytic leukemia and HCL, IFN-a shortens the half-life of TNF mRNA (27) . These studies suggest that IFN-a may interrupt a TNF autocrine growth mechanism in HCL. However, other studies present conflicting or alternative mechanisms of IFN's effects; i.e., it may act in HCL by affecting CD20 phosphorylation (57), or by inducing differentiation (58) . Moreover, some studies directly contradict the notion that IFN-a interrupts a TNF autocrine growth mechanism in HCL and suggest that IFN-a both enhances the expression of cell surface TNF and IL-6 receptors and augments TNF production by HCs (59) (60) (61) . The cytotoxic effect of 2-cda in HCL is proposed to result from the accumulation of its 5'-triphosphate form in cells with high deoxycytidine kinase activity, resulting in DNA strand breaks and ATP depletion (55) . The present data suggest that future studies should examine whether either IFN-a or 2-cda may also be acting via their effects on IL-6 mediated growth of HCL.
The mechanism whereby TNF induces IL-6 in HCL is undefined. There are several potential transcriptional control elements, such as glucocorticoid-responsive elements, an AP-I binding site, a c-fos serum-responsive element homology, a cyclic AMP-responsive element, and an NF-KB binding site within the IL-6 promoter (62). Previous studies suggest that the induction of IL-6 by TNF appears to involve an IL-6 promoter element termed inflammatory lymphokine-responsive element (ILRE; 63). The ILRE sequence is highly homologous to NF-KB transcription factor binding motifs and binds an IL-1-TNF-a inducible nuclear factor. The sequence specificities, binding characteristics, and subcellular localizations ofthis factor are indistinguishable from those of NFKB. In addition, mutations of the ILRE sequence that impair the binding of this nuclear factor abolish the induction of IL-6 gene expression by IL-1 and TNF-a in vivo (64, 65) Thus, a nuclear factor indistinguishable from NF-KB is involved in the transcriptional activation of the IL-6 gene by IL-1 and TNF-a (66). Future experiments using appropriate IL-6 promoter constructs in CAT reporter assays will determine whether the effects of TNF-a on IL-6 induction in HCs similarly involve activation of the IL-RE sequence within the IL-6 promoter.
